Department of Pharmacy, University of Patras, GR 26500, Patras, Greece.
Department of Biochemistry, Hellenic Pasteur Institute, 127 Vass. Sofias Avenue, GR 11521, Athens, Greece.
J Neuroimmunol. 2014 Feb 15;267(1-2):1-6. doi: 10.1016/j.jneuroim.2013.11.001. Epub 2013 Nov 10.
Myasthenia gravis is an autoimmune disease usually caused by autoantibodies against the muscle nicotinic acetylcholine receptor (nAChR). Current treatments are not specific, and thus often cause side effects. Here, we elaborate on our previous findings on antigen specific immunoadsorption towards scaling up the method as well as testing whole blood apheresis. The average percent of plasma or whole blood immunoadsorption was up to 79.5%±2.9. Moreover, neither pyrogens were co-administered nor did complement activation occur after immunoadsorption. Thus, antigen-specific apheresis of anti-AChR autoantibodies seems a safe and effective treatment for myasthenia gravis that can be scaled up for clinical testing.
重症肌无力是一种自身免疫性疾病，通常由针对肌肉烟碱型乙酰胆碱受体 (nAChR) 的自身抗体引起。目前的治疗方法不具有特异性，因此经常会引起副作用。在这里，我们详细阐述了之前关于针对抗原特异性免疫吸附的发现，以便将该方法放大以及测试全血血浆吸附。平均血浆或全血免疫吸附率高达 79.5%±2.9。此外，免疫吸附后既没有同时给予热原，也没有补体激活。因此，针对抗 AChR 自身抗体的抗原特异性血浆吸附似乎是一种安全有效的重症肌无力治疗方法，可以放大进行临床试验。
